Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04796012 · ClinicalTrials.gov registry record · Phase 1
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
A Phase 1 study of Solid Tumor and Rhabdomyosarcoma, sponsored by University of Texas Southwestern Medical Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 7
- Study locations
NCT04796012 is a Phase 1 study of Solid Tumor and Rhabdomyosarcoma that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 23 participants, below the 222-participant average among 196 other Solid Tumor trials with a reported enrollment target (90% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT04796012, a Phase 1 study of Solid Tumor and Rhabdomyosarcoma, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 7
- Study locations
Study Summary
This trial is a multi-center, non-randomized, open-label Phase I/II study evaluating the feasibility and efficacy of vincristine, irinotecan, temozolomide, and atezolizumab in children with relapsed/refractory solid tumors.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG Temozolomide
- DRUG Vincristine
- DRUG Irinotecan
Study Locations (7)
Texas
- The University of Texas Southwestern Medical Center - Dallas
- Texas Children's Hospital - Houston
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Massachusetts
- Boston Children's Hospital - Boston
Ohio
- Cincinnati Children's Hospital - Cincinnati
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Washington
- Seattle Children's - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2023-04-18 |
| Est. Completion | 2027-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04796012
The ClinicalTrials.gov registry entry for NCT04796012 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 222-participant average among 196 other Solid Tumor trials with a reported enrollment target (90% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Solid Tumor appearing as the primary indexed condition, and to 4 interventions - of which Atezolizumab is the first listed.
NCT04796012 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Texas, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04796012 about?
NCT04796012 is a clinical study titled "VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors". This trial is a multi-center, non-randomized, open-label Phase I/II study evaluating the feasibility and efficacy of vincristine, irinotecan, temozolomide, and atezolizumab in children with relapsed/refractory solid tumors.
What is the current status of trial NCT04796012?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2023-04-18. Estimated completion is 2027-01.
What conditions does trial NCT04796012 study?
This clinical trial studies the following conditions: Solid Tumor, Rhabdomyosarcoma.
What interventions are being tested in trial NCT04796012?
The interventions under investigation include: Atezolizumab (DRUG), Temozolomide (DRUG), Vincristine (DRUG), Irinotecan (DRUG).
Who is sponsoring clinical trial NCT04796012?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04796012 being conducted?
This trial has 7 study locations across Illinois, Massachusetts, Ohio, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.